Accelerating The Development Of Enabled Formulations For Poorly Soluble Drugs Using Translational Pharmaceutics®

New drugs advancing through development often face efficacy issues caused by insufficient aqueous solubility. The traditional in-vitro analysis and pre-clinical studies used are notoriously poor at predicting drug behavior in humans, and  the cost and time expended in this process can be considerable. The selection of formulation prototypes to overcome a solubility issue using these tools also carries a significant risk of non-resolution in subsequent clinical testing.

Explore how the Translational Pharmaceutics® platform — which integrates drug substance, drug product and clinical testing activities within a single organization — accelerates development timelines and reduces project costs, helping deliver positive clinical outcomes earlier.